Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

  • STATUS
    Not Recruiting
  • participants needed
    125
  • sponsor
    Eisai Co., Ltd.
Updated on 21 June 2021
cancer
measurable disease
carcinoma
breast cancer
endocrine therapy
lung cancer
colony stimulating factor
neutrophil count
hormone therapy
blood transfusion
cancer treatment
solid tumor
alopecia
platelet transfusion
kidney function test

Summary

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and in participants with adenoid cystic carcinoma (ACC), gastric cancer (GC), esophageal cancer (EGC), and small cell lung cancer (SCLC) in the expansion part 2, 3, 4, and 5.

Details
Condition Solid Tumor
Treatment E7389-LF
Clinical Study IdentifierNCT03207672
SponsorEisai Co., Ltd.
Last Modified on21 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note